Dynavax Reports Third Quarter 2024 Financial Results and Provides Business Updates

HEPLISAV-B® quarterly net product revenue of $79.3 million, representing 27% year-over-year growth Hepatitis B adult vaccine market expected to expand to a peak of over$ 900 million by 2030, with HEPLISAV-B expected to achieve at least 60% estimated total market share Expect positive net income in 2024, achieving full year profitability Strengthened cash position to $764 million in Q3'24$ 200 million share repurchase program announced as part of balanced capital allocation strategy Conference call today ...